Refine your search

  • Books (24)

to

Custom price range (£)

to

Abbott Iii Thomas A (24 results)

Author: 
Refine with Advanced Search
  • Language: English

    Published by Springer US, 1995

    0792395409 / 9780792395409

    • Hardcover

    Seller: Buchpark, Trebbin, GermanyBuchpark

    5-star seller
    Contact seller

    Condition: Used - Fine

    Original price: £ 16.62
    10% off

    Current price: £ 14.96

    £ 87.53 shipping 
    Ships from Germany to U.S.A.

    Quantity: 3 available

    Condition: Sehr gut. Zustand: Sehr gut | Seiten: 276 | Sprache: Englisch | Produktart: Bücher | 5 care reforms. Part II: Price Regulation The second partofthis volume examines the role ofprice regulation in controlling health care costs. It contains three chapters. In chapter seven, I examine the alternatives for regulating pharmaceutical prices. In chapter eight, Jack Hadley examines the impactofvarious forms ofhospital price regulation; while in chapter nine,MarkPaulyexaminestheroleofpriceregulation incontrollingphysician fees. Chapter seven focuses on the issue of regulating pharmaceutical prices. There are two key issues examined in this paper. First, is there a clear need for price regulation, and second, can price regulation work in this industry? In response to the first question, I come to the conclusion that the proponents ofprice regulation have not really proven their case. Although the financial returns in the pharmaceu­ tical industry have been slightly higher than expected during the 1970s and 1980s, there is not overwhelming evidence of"price gouging" or excessive profits on the part of the industry. In response to the second question, the answer is clearly no. The traditional approaches to price regulation will not have the intended affect of eliminating excess profits from the industry while maintaining the incentives for research and development. First, rate-of-return regulation, the most natural approach, would result in many adverse incentives-includingexcessive investment in research and developmentinorderto inflatetheratebaseused tocalculatedtheallowablereturns.…

  • Language: English

    Published by Springer US, 1995

    0792395409 / 9780792395409

    • Hardcover

    Seller: Buchpark, Trebbin, GermanyBuchpark

    5-star seller
    Contact seller

    Condition: Used

    Original price: £ 17.12
    10% off

    Current price: £ 15.41

    £ 87.53 shipping 
    Ships from Germany to U.S.A.

    Quantity: 1 available

    Condition: Hervorragend. Zustand: Hervorragend | Seiten: 276 | Sprache: Englisch | Produktart: Bücher | 5 care reforms. Part II: Price Regulation The second partofthis volume examines the role ofprice regulation in controlling health care costs. It contains three chapters. In chapter seven, I examine the alternatives for regulating pharmaceutical prices. In chapter eight, Jack Hadley examines the impactofvarious forms ofhospital price regulation; while in chapter nine,MarkPaulyexaminestheroleofpriceregulation incontrollingphysician fees. Chapter seven focuses on the issue of regulating pharmaceutical prices. There are two key issues examined in this paper. First, is there a clear need for price regulation, and second, can price regulation work in this industry? In response to the first question, I come to the conclusion that the proponents ofprice regulation have not really proven their case. Although the financial returns in the pharmaceu­ tical industry have been slightly higher than expected during the 1970s and 1980s, there is not overwhelming evidence of"price gouging" or excessive profits on the part of the industry. In response to the second question, the answer is clearly no. The traditional approaches to price regulation will not have the intended affect of eliminating excess profits from the industry while maintaining the incentives for research and development. First, rate-of-return regulation, the most natural approach, would result in many adverse incentives-includingexcessive investment in research and developmentinorderto inflatetheratebaseused tocalculatedtheallowablereturns.…

  • Language: English

    Published by Springer, 1995

    0792395409 / 9780792395409

    • Hardcover

    Seller: GreatBookPrices, Columbia, MD, U.S.A.GreatBookPrices

    5-star seller
    Contact seller

    Condition: Used - As new

    £ 105.55

    £ 1.96 shipping 
    Ships within U.S.A.

    Quantity: 15 available

    Condition: As New. Unread book in perfect condition.

  • Language: English

    Published by Springer, 2012

    1461359325 / 9781461359326

    • Softcover

    Seller: GreatBookPrices, Columbia, MD, U.S.A.GreatBookPrices

    5-star seller
    Contact seller

    Condition: New

    £ 111.90

    £ 1.96 shipping 
    Ships within U.S.A.

    Quantity: 15 available

    Condition: New.

  • Language: English

    Published by Springer, 1995

    0792395409 / 9780792395409

    • Hardcover

    Seller: GreatBookPrices, Columbia, MD, U.S.A.GreatBookPrices

    5-star seller
    Contact seller

    Condition: New

    £ 121.33

    £ 1.96 shipping 
    Ships within U.S.A.

    Quantity: 15 available

    Condition: New.

  • Language: English

    Published by Kluwer Academic Publishers, 1995

    0792395409 / 9780792395409

    • Hardcover

    Seller: Kennys Bookshop and Art Galleries Ltd., Galway, GY, IrelandKennys Bookshop and Art Galleries Ltd.

    5-star seller
    Contact seller

    Condition: New

    £ 115.56

    £ 7.92 shipping 
    Ships from Ireland to U.S.A.

    Quantity: 15 available

    Condition: New. Deals in an useful way with some of the issues involved in the debate over health care reform. This book brings together some of the researchers to discuss alternative ways of restructuring the health care industries, and alternative methods for regulating these industries to achieve the objectives of increased access and constraining costs. Editor(s): Abbott III, Thomas A. Series: Topics in Regulatory Economics and Policy. Num Pages: 261 pages, biography. BIC Classification: KJU; MBP. Category: (P) Professional & Vocational; (UP) Postgraduate, Research & Scholarly; (UU) Undergraduate. Dimension: 229 x 152 x 19. Weight in Grams: 576. . 1995. Hardback. . . . .…

  • Language: English

    Published by Springer, 2012

    1461359325 / 9781461359326

    • Softcover

    Seller: Books Puddle, Woodside, NY, U.S.A.Books Puddle

    4-star seller
    Contact seller

    Condition: New

    £ 131.27

    £ 2.96 shipping 
    Ships within U.S.A.

    Quantity: 4 available

    Condition: New. pp. 278.

  • Language: English

    Published by Springer, 1995

    0792395409 / 9780792395409

    • Hardcover

    Seller: Books Puddle, Woodside, NY, U.S.A.Books Puddle

    4-star seller
    Contact seller

    Condition: New

    £ 132.20

    £ 2.96 shipping 
    Ships within U.S.A.

    Quantity: 4 available

    Condition: New. pp. 276.

  • Language: English

    Published by Springer, 1995

    0792395409 / 9780792395409

    • Hardcover

    Seller: AHA-BUCH GmbH, Einbeck, GermanyAHA-BUCH GmbH

    5-star seller
    Contact seller

    Condition: New

    £ 107.21

    £ 29.18 shipping 
    Ships from Germany to U.S.A.

    Quantity: 1 available

    Buch. Condition: Neu. Druck auf Anfrage Neuware - Printed after ordering - 5 care reforms. Part II: Price Regulation The second partofthis volume examines the role ofprice regulation in controlling health care costs. It contains three chapters. In chapter seven, I examine the alternatives for regulating pharmaceutical prices. In chapter eight, Jack Hadley examines the impactofvarious forms ofhospital price regulation; while in chapter nine,MarkPaulyexaminestheroleofpriceregulation incontrollingphysician fees. Chapter seven focuses on the issue of regulating pharmaceutical prices. There are two key issues examined in this paper. First, is there a clear need for price regulation, and second, can price regulation work in this industry In response to the first question, I come to the conclusion that the proponents ofprice regulation have not really proven their case. Although the financial returns in the pharmaceu tical industry have been slightly higher than expected during the 1970s and 1980s, there is not overwhelming evidence of'price gouging' or excessive profits on the part of the industry. In response to the second question, the answer is clearly no. The traditional approaches to price regulation will not have the intended affect of eliminating excess profits from the industry while maintaining the incentives for research and development. First, rate-of-return regulation, the most natural approach, would result in many adverse incentives-includingexcessive investment in research and developmentinorderto inflatetheratebaseused tocalculatedtheallowablereturns.…

  • Language: English

    Published by Springer, 2012

    1461359325 / 9781461359326

    • Softcover

    Seller: AHA-BUCH GmbH, Einbeck, GermanyAHA-BUCH GmbH

    5-star seller
    Contact seller

    Condition: New

    £ 107.21

    £ 29.18 shipping 
    Ships from Germany to U.S.A.

    Quantity: 1 available

    Taschenbuch. Condition: Neu. Druck auf Anfrage Neuware - Printed after ordering - 5 care reforms. Part II: Price Regulation The second partofthis volume examines the role ofprice regulation in controlling health care costs. It contains three chapters. In chapter seven, I examine the alternatives for regulating pharmaceutical prices. In chapter eight, Jack Hadley examines the impactofvarious forms ofhospital price regulation; while in chapter nine,MarkPaulyexaminestheroleofpriceregulation incontrollingphysician fees. Chapter seven focuses on the issue of regulating pharmaceutical prices. There are two key issues examined in this paper. First, is there a clear need for price regulation, and second, can price regulation work in this industry In response to the first question, I come to the conclusion that the proponents ofprice regulation have not really proven their case. Although the financial returns in the pharmaceu tical industry have been slightly higher than expected during the 1970s and 1980s, there is not overwhelming evidence of'price gouging' or excessive profits on the part of the industry. In response to the second question, the answer is clearly no. The traditional approaches to price regulation will not have the intended affect of eliminating excess profits from the industry while maintaining the incentives for research and development. First, rate-of-return regulation, the most natural approach, would result in many adverse incentives-includingexcessive investment in research and developmentinorderto inflatetheratebaseused tocalculatedtheallowablereturns.…

  • Language: English

    Published by Kluwer Academic Publishers, 1995

    0792395409 / 9780792395409

    • Hardcover

    Seller: Kennys Bookstore, Olney, MD, U.S.A.Kennys Bookstore

    5-star seller
    Contact seller

    Condition: New

    £ 144.22

    £ 7.79 shipping 
    Ships within U.S.A.

    Quantity: 15 available

    Condition: New. Deals in an useful way with some of the issues involved in the debate over health care reform. This book brings together some of the researchers to discuss alternative ways of restructuring the health care industries, and alternative methods for regulating these industries to achieve the objectives of increased access and constraining costs. Editor(s): Abbott III, Thomas A. Series: Topics in Regulatory Economics and Policy. Num Pages: 261 pages, biography. BIC Classification: KJU; MBP. Category: (P) Professional & Vocational; (UP) Postgraduate, Research & Scholarly; (UU) Undergraduate. Dimension: 229 x 152 x 19. Weight in Grams: 576. . 1995. Hardback. . . . . Books ship from the US and Ireland.…

  • Language: English

    Published by Springer, 2012

    1461359325 / 9781461359326

    • Softcover

    Seller: Mispah books, Redhill, SURRE, United KingdomMispah books

    4-star seller
    Contact seller

    Condition: Used - As new

    £ 179.00

    £ 25.00 shipping 
    Ships from United Kingdom to U.S.A.

    Quantity: 1 available

    Paperback. Condition: Like New. LIKE NEW. SHIPS FROM MULTIPLE LOCATIONS. book.

  • Language: English

    Published by Springer, 2012

    1461359325 / 9781461359326

    • Softcover

    Seller: GreatBookPrices, Columbia, MD, U.S.A.GreatBookPrices

    5-star seller
    Contact seller

    Condition: Used - As new

    £ 212.92

    £ 1.96 shipping 
    Ships within U.S.A.

    Quantity: 15 available

    Condition: As New. Unread book in perfect condition.

  • Language: English

    Published by Springer, 2012

    1461359325 / 9781461359326

    • Softcover
    • Print on Demand

    Seller: Brook Bookstore On Demand, Napoli, NA, ItalyBrook Bookstore On Demand

    5-star seller
    Contact seller

    Condition: New

    £ 74.05

    £ 4.58 shipping 
    Ships from Italy to U.S.A.

    Quantity: Over 20 available

    Condition: new. Questo è un articolo print on demand.

  • Language: English

    Published by Springer US, Springer US Sep 2012, 2012

    1461359325 / 9781461359326

    • Softcover
    • Print on Demand

    Seller: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, GermanyBuchWeltWeit Ludwig Meier e.K.

    5-star seller
    Contact seller

    Condition: New

    £ 91.87

    £ 19.17 shipping 
    Ships from Germany to U.S.A.

    Quantity: 2 available

    Taschenbuch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -5 care reforms. Part II: Price Regulation The second partofthis volume examines the role ofprice regulation in controlling health care costs. It contains three chapters. In chapter seven, I examine the alternatives for regulating pharmaceutical prices. In chapter eight, Jack Hadley examines the impactofvarious forms ofhospital price regulation; while in chapter nine,MarkPaulyexaminestheroleofpriceregulation incontrollingphysician fees. Chapter seven focuses on the issue of regulating pharmaceutical prices. There are two key issues examined in this paper. First, is there a clear need for price regulation, and second, can price regulation work in this industry In response to the first question, I come to the conclusion that the proponents ofprice regulation have not really proven their case. Although the financial returns in the pharmaceu tical industry have been slightly higher than expected during the 1970s and 1980s, there is not overwhelming evidence of'price gouging' or excessive profits on the part of the industry. In response to the second question, the answer is clearly no. The traditional approaches to price regulation will not have the intended affect of eliminating excess profits from the industry while maintaining the incentives for research and development. First, rate-of-return regulation, the most natural approach, would result in many adverse incentives-includingexcessive investment in research and developmentinorderto inflatetheratebaseused tocalculatedtheallowablereturns. 276 pp. Englisch.…

  • Language: English

    Published by Springer US, 2012

    1461359325 / 9781461359326

    • Softcover
    • Print on Demand

    Seller: moluna, Greven, Germanymoluna

    5-star seller
    Contact seller

    Condition: New

    £ 79.23

    £ 40.84 shipping 
    Ships from Germany to U.S.A.

    Quantity: Over 20 available

    Condition: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. 5 care reforms. Part II: Price Regulation The second partofthis volume examines the role ofprice regulation in controlling health care costs. It contains three chapters. In chapter seven, I examine the alternatives for regulating pharmaceutical prices. In c. …

  • Language: English

    Published by Springer US, 1995

    0792395409 / 9780792395409

    • Hardcover
    • Print on Demand

    Seller: moluna, Greven, Germanymoluna

    5-star seller
    Contact seller

    Condition: New

    £ 79.23

    £ 40.84 shipping 
    Ships from Germany to U.S.A.

    Quantity: Over 20 available

    Gebunden. Condition: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. 5 care reforms. Part II: Price Regulation The second partofthis volume examines the role ofprice regulation in controlling health care costs. It contains three chapters. In chapter seven, I examine the alternatives for regulating pharmaceutical prices. In c.…

  • Language: English

    Published by Springer US, Springer US Feb 1995, 1995

    0792395409 / 9780792395409

    • Hardcover
    • Print on Demand

    Seller: buchversandmimpf2000, Emtmannsberg, BAYE, Germanybuchversandmimpf2000

    5-star seller
    Contact seller

    Condition: New

    £ 91.87

    £ 50.02 shipping 
    Ships from Germany to U.S.A.

    Quantity: 1 available

    Buch. Condition: Neu. This item is printed on demand - Print on Demand Titel. Neuware -5 care reforms. Part II: Price Regulation The second partofthis volume examines the role ofprice regulation in controlling health care costs. It contains three chapters. In chapter seven, I examine the alternatives for regulating pharmaceutical prices. In chapter eight, Jack Hadley examines the impactofvarious forms ofhospital price regulation; while in chapter nine,MarkPaulyexaminestheroleofpriceregulation incontrollingphysician fees. Chapter seven focuses on the issue of regulating pharmaceutical prices. There are two key issues examined in this paper. First, is there a clear need for price regulation, and second, can price regulation work in this industry In response to the first question, I come to the conclusion that the proponents ofprice regulation have not really proven their case. Although the financial returns in the pharmaceu tical industry have been slightly higher than expected during the 1970s and 1980s, there is not overwhelming evidence of'price gouging' or excessive profits on the part of the industry. In response to the second question, the answer is clearly no. The traditional approaches to price regulation will not have the intended affect of eliminating excess profits from the industry while maintaining the incentives for research and development. First, rate-of-return regulation, the most natural approach, would result in many adverse incentives-includingexcessive investment in research and developmentinorderto inflatetheratebaseused tocalculatedtheallowablereturns.Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 276 pp. Englisch.…

  • Language: English

    Published by Springer US, Humana Sep 2012, 2012

    1461359325 / 9781461359326

    • Softcover
    • Print on Demand

    Seller: buchversandmimpf2000, Emtmannsberg, BAYE, Germanybuchversandmimpf2000

    5-star seller
    Contact seller

    Condition: New

    £ 91.87

    £ 50.02 shipping 
    Ships from Germany to U.S.A.

    Quantity: 1 available

    Taschenbuch. Condition: Neu. This item is printed on demand - Print on Demand Titel. Neuware -5 care reforms. Part II: Price Regulation The second partofthis volume examines the role ofprice regulation in controlling health care costs. It contains three chapters. In chapter seven, I examine the alternatives for regulating pharmaceutical prices. In chapter eight, Jack Hadley examines the impactofvarious forms ofhospital price regulation; while in chapter nine,MarkPaulyexaminestheroleofpriceregulation incontrollingphysician fees. Chapter seven focuses on the issue of regulating pharmaceutical prices. There are two key issues examined in this paper. First, is there a clear need for price regulation, and second, can price regulation work in this industry In response to the first question, I come to the conclusion that the proponents ofprice regulation have not really proven their case. Although the financial returns in the pharmaceu tical industry have been slightly higher than expected during the 1970s and 1980s, there is not overwhelming evidence of'price gouging' or excessive profits on the part of the industry. In response to the second question, the answer is clearly no. The traditional approaches to price regulation will not have the intended affect of eliminating excess profits from the industry while maintaining the incentives for research and development. First, rate-of-return regulation, the most natural approach, would result in many adverse incentives-includingexcessive investment in research and developmentinorderto inflatetheratebaseused tocalculatedtheallowablereturns.Springer-Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 276 pp. Englisch.…

  • Language: English

    Published by Springer, 2012

    1461359325 / 9781461359326

    • Softcover
    • Print on Demand

    Seller: Majestic Books, Hounslow, United KingdomMajestic Books

    4-star seller
    Contact seller

    Condition: New

    £ 137.53

    £ 6.50 shipping 
    Ships from United Kingdom to U.S.A.

    Quantity: 4 available

    Condition: New. Print on Demand pp. 278 23:B&W 6 x 9 in or 229 x 152 mm Perfect Bound on White w/Gloss Lam.

  • Language: English

    Published by Springer, 1995

    0792395409 / 9780792395409

    • Hardcover
    • Print on Demand

    Seller: Majestic Books, Hounslow, United KingdomMajestic Books

    4-star seller
    Contact seller

    Condition: New

    £ 138.29

    £ 6.50 shipping 
    Ships from United Kingdom to U.S.A.

    Quantity: 4 available

    Condition: New. Print on Demand pp. 276 9:B&W 6 x 9 in or 229 x 152 mm Case Laminate on Creme w/Gloss Lam.

  • Language: English

    Published by Springer, 2012

    1461359325 / 9781461359326

    • Softcover
    • Print on Demand

    Seller: Biblios, frankfurt am main, HESSE, GermanyBiblios

    4-star seller
    Contact seller

    Condition: New

    £ 142.52

    £ 8.29 shipping 
    Ships from Germany to U.S.A.

    Quantity: 4 available

    Condition: New. PRINT ON DEMAND pp. 278.

  • Language: English

    Published by Springer, 1995

    0792395409 / 9780792395409

    • Hardcover
    • Print on Demand

    Seller: Biblios, frankfurt am main, HESSE, GermanyBiblios

    4-star seller
    Contact seller

    Condition: New

    £ 143.24

    £ 8.29 shipping 
    Ships from Germany to U.S.A.

    Quantity: 4 available

    Condition: New. PRINT ON DEMAND pp. 276.

  • Language: English

    Published by Springer Feb 1995, 1995

    0792395409 / 9780792395409

    • Hardcover
    • Print on Demand

    Seller: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, GermanyBuchWeltWeit Ludwig Meier e.K.

    5-star seller
    Contact seller

    Condition: New

    £ 133.17

    £ 19.17 shipping 
    Ships from Germany to U.S.A.

    Quantity: 2 available

    Buch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -5 care reforms. Part II: Price Regulation The second partofthis volume examines the role ofprice regulation in controlling health care costs. It contains three chapters. In chapter seven, I examine the alternatives for regulating pharmaceutical prices. In chapter eight, Jack Hadley examines the impactofvarious forms ofhospital price regulation; while in chapter nine,MarkPaulyexaminestheroleofpriceregulation incontrollingphysician fees. Chapter seven focuses on the issue of regulating pharmaceutical prices. There are two key issues examined in this paper. First, is there a clear need for price regulation, and second, can price regulation work in this industry In response to the first question, I come to the conclusion that the proponents ofprice regulation have not really proven their case. Although the financial returns in the pharmaceu tical industry have been slightly higher than expected during the 1970s and 1980s, there is not overwhelming evidence of'price gouging' or excessive profits on the part of the industry. In response to the second question, the answer is clearly no. The traditional approaches to price regulation will not have the intended affect of eliminating excess profits from the industry while maintaining the incentives for research and development. First, rate-of-return regulation, the most natural approach, would result in many adverse incentives-includingexcessive investment in research and developmentinorderto inflatetheratebaseused tocalculatedtheallowablereturns. 276 pp. Englisch.…